Hologic's (HOLX) "Hold (C-)" Rating Reaffirmed at Weiss Ratings

Hologic (NASDAQ:HOLX - Get Free Report)'s stock had its "hold (c-)" rating reissued by equities research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other brokerages also recently commented on HOLX. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and boosted their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Evercore ISI set a $78.00 price target on shares of Hologic and gave the company an "outperform" rating in a research note on Tuesday. Stephens reaffirmed an "overweight" rating and issued a $78.00 price target on shares of Hologic in a research note on Thursday, September 18th. Finally, Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $80.15.

Hologic Stock Performance

Shares of HOLX stock opened at $68.34 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock has a market cap of $15.20 billion, a PE ratio of 28.36, a price-to-earnings-growth ratio of 2.32 and a beta of 0.63. The stock has a 50-day moving average of $67.10 and a 200-day moving average of $63.22. Hologic has a one year low of $51.90 and a one year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, sell-side analysts expect that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.88% of the stock is owned by company insiders.

Institutional Trading of Hologic

Large investors have recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC acquired a new stake in Hologic in the second quarter valued at $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 273 shares during the period. Loomis Sayles & Co. L P acquired a new position in Hologic during the second quarter worth approximately $33,000. Zions Bancorporation National Association UT acquired a new position in Hologic during the first quarter worth approximately $34,000. Finally, Cromwell Holdings LLC increased its position in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock worth $38,000 after buying an additional 436 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.